Presentation is loading. Please wait.

Presentation is loading. Please wait.

Radioembolization for hepatocellular carcinoma

Similar presentations


Presentation on theme: "Radioembolization for hepatocellular carcinoma"— Presentation transcript:

1 Radioembolization for hepatocellular carcinoma
Bruno Sangro, Mercedes Iñarrairaegui, Jose I. Bilbao  Journal of Hepatology  Volume 56, Issue 2, Pages (February 2012) DOI: /j.jhep Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

2 Fig. 1 Liver volume exposed to radiation is defined by the arteries into which radioactive microspheres are injected. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

3 Fig. 2 (Chemo)embolization and radioembolization. Upper panel: small (35μm) isotope-loaded particles are delivered into the smallest intratumoral blood vessels with the aim of delivering short-range irradiation in radioembolization. Medium (100–500μm) drug-eluting or simple particles are delivered into the medium-size vessels that irrigate tumor nodules with the aim of producing ischemia and eventually expose tumor cells to high concentrations of cytotoxic agents in (chemo)embolization. Lower panel: size comparison between microspheres used for arterial (chemo)embolization and radioembolization. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

4 Fig. 3 99mTc-MAA scan of a patient with a large tumor involving the right lobe treated in a lobar fashion. (A) A planar image from where lung shunting is calculated; (B) a SPECT image that reveal an intense uptake by the tumor (high tumor to non-tumor ratio); (C) an MR image of the tumor at baseline; and (D) an MR image of the tumor 2years later showing an intense partial response after 3 sessions of radioembolization. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

5 Fig. 4 Comparison between median overall survival observed in comparable subgroups of patients treated by radioembolization and sorafenib. Data for 299 sorafenib-treated patients was obtained from subanalysis of the SHARP trial. Data for 189 radioembolization-treated patients was obtained from subanalysis of a cohort of patients fulfilling the same inclusion criteria, namely Child-Pugh class A and either BCLC stage C or BCLC stage B with prior TACE or bulky disease (bilobar or >5 nodules) [33,47,49–52]. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

6 Fig. 5 Median overall survival of HCC patients treated with radioembolization, TACE, and sorafenib according to BCLC stage. Journal of Hepatology  , DOI: ( /j.jhep ) Copyright © 2011 European Association for the Study of the Liver Terms and Conditions

7 Journal of Hepatology 2012 56, 464-473DOI: (10. 1016/j. jhep. 2011. 07
Copyright © 2011 European Association for the Study of the Liver Terms and Conditions


Download ppt "Radioembolization for hepatocellular carcinoma"

Similar presentations


Ads by Google